A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Patricia Cheung et al.|Clinical Cancer Research|2024Cited by 50
Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosisMarc Sorigué, Xavier Calvo, Leonor Arenillas et al.|Leukemia Research|2021Cited by 3
Supplementary Table S1 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Sagar Lonial et al.|Unknown|2024Cited by 1
Data from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Sagar Lonial et al.|Unknown|2024Cited by 0
Supplementary Table S2 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Sagar Lonial et al.|Unknown|2024Cited by 0